Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Macimorelin - COSCIENS Biopharma

Next Previous
Drug Profile

Macimorelin - COSCIENS Biopharma

Alternative Names: AEZS-130; ARD-07; D-87575; EP-01572; EP-1572; Ghryvelin; JMARD-07; JMV-1843; Macimorelin acetate; Macrilen; Solorel

Latest Information Update: 26 Nov 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AEterna Zentaris Inc
  • Developer Consilient Health; COSCIENS Biopharma; Novo Nordisk; University of Queensland
  • Class Amides; Carboxylic acids; Diagnostic agents; Indoles; Oligopeptides; Small molecules
  • Mechanism of Action Ghrelin receptor agonists; Ghrelin receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Somatotropin deficiency
  • New Molecular Entity Yes
  • Available For Licensing Yes - Somatotropin deficiency

Highest Development Phases

  • Marketed Somatotropin deficiency
  • Phase II Cachexia
  • Discontinued Amyotrophic lateral sclerosis

Most Recent Events

  • 11 Nov 2025 Macimorelin - COSCIENS Biopharma is available for licensing as of 11 Nov 2025
  • 14 Aug 2025 COSCIENS Biopharma plans a Type C meeting with the US FDA to determine the feasibility of a possible path forward for pediatric somatotropin deficiency in the second half of 2025
  • 24 Dec 2024 Discontinued - Preclinical for Amyotrophic lateral sclerosis in Australia (unspecified route)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top